Antiarrhythmic efficacy and electrophysiologic actions of amiodarone in patients with life-threatening ventricular arrhythmias: Potent suppression of spontaneously occurring tachyarrhythmias versus inconsistent abolition of induced ventricular tachycardia

1982 ◽  
Vol 103 (6) ◽  
pp. 950-959 ◽  
Author(s):  
Koonlawee Nademanee ◽  
JoAnn Hendrickson ◽  
Ramaswamy Kannan ◽  
Bramah N. Singh
Keyword(s):  
Ventricular Tachycardia ◽  
Ventricular Arrhythmias ◽  
Life Threatening ◽  
Antiarrhythmic Efficacy

1175Structural progression increases the risk of ventricular arrhythmias in patients with arrhythmogenic cardiomyopathy

2019 ◽  
Vol 40 (Supplement_1) ◽  
Author(s):  
M Chivulescu ◽  
Ø.H Lie ◽  
H Skulstad ◽  
B A Popescu ◽  
R O Jurcut ◽  
...  
Keyword(s):  
Ventricular Tachycardia ◽  
Ventricular Arrhythmias ◽  
Arrhythmogenic Cardiomyopathy ◽  
Cardioverter Defibrillator ◽  
Structural Progression ◽  
Life Threatening ◽  
Arrhythmic Event ◽  
History Of ◽  
Structural Disease

Abstract Background Arrhythmogenic cardiomyopathy (AC) is an inheritable cardiomyopathy with incomplete penetrance, variable phenotype severity and poorly described disease progression. It is characterized by high risk of life-threatening ventricular arrhythmias and sudden cardiac death in young individuals. Risk stratification and selection of patients presenting without history of life-threatening arrhythmic events for cardioverter-defibrillator implantation in primary prevention remains challenging. Purpose We aimed to assess the impact of disease progression on arrhythmic outcomes in AC patients. Methods We included consecutive AC probands and mutation-positive family members with at least one complete follow-up evaluation. Echocardiographic and electrical parameters were defined according to the 2010 Revised Task Force criteria at inclusion and at last follow-up. Structural progression was defined as development of new echocardiographic diagnostic criteria. Electrical progression was defined as the development of new diagnostic depolarization, repolarization and/or premature ventricular complex count criteria during follow-up. Non-sustained ventricular tachycardia or ventricular tachycardia occurring during follow-up defined incident ventricular arrhythmic events. Results We included a total of 144 patients (48% female, 47% probands, 40±16 years old). At inclusion, 54 patients (37%) had a history of arrhythmic events, 30 patients (21%) had overt structural disease and 114 (79%) had no or minor structural disease. During 7.0 (IQR: 4.5 to 9.4) years of follow-up, 49 patients (43%) with no or minor structural disease at inclusion developed new structural criteria being defined as progressors. Among 80 participants with no or minor structural disease and no arrhythmic history at inclusion, a first arrhythmic event occurred in 14 (17%). The incidence of arrhythmic events was higher in progressors (11/27, 41%) than in non-progressors (3/53, 6%) (p<0.001) (Figure). Structural progression was associated with higher risk of first arrhythmic events during follow-up when adjusted for sex, age at inclusion and follow-up duration, independent of electrical progression (7.6, 95% CI [1.5, 37.2], P=0.01). Incident arrhythmic events distribution Conclusion Almost half of patients without overt structural cardiac disease at genetic diagnosis develop new structural criteria during 7 years follow-up and 17% experienced their first ventricular arrhythmic event. Structural progression was independently associated with ventricular arrhythmic events during follow-up. These findings highlight the increased risk of arrhythmias when structural abnormalities are detected. Their finding may initiate the evaluation for primary prevention cardioverter-defibrillator implantation.

scholarly journals Bidirectional ventricular tachycardia: what is it?

2020 ◽  
Vol 26 (4) ◽  
pp. 59-63
Author(s):  
Yu. V. Shubik
Keyword(s):  
Ventricular Tachycardia ◽  
Ventricular Arrhythmias ◽  
Torsade De Pointes ◽  
Life Threatening

The differences between polymorphic spindle-shaped (such as “pirouette”, “torsade de pointes”) and polymorphic bidirectional ventricular tachycardia are discussed, examples of these life-threatening ventricular arrhythmias are given.

scholarly journals Ventricular Tachycardia in Congenital Adrenal Hyperplasia

2002 ◽  
Vol 30 (3) ◽  
pp. 380-381 ◽  
Author(s):  
V. S. Virdi ◽  
B. Bharti ◽  
B. Poddar ◽  
S. Basu ◽  
V. R. Parmar
Keyword(s):  
Ventricular Tachycardia ◽  
Congenital Adrenal Hyperplasia ◽  
Ventricular Arrhythmias ◽  
Adrenal Hyperplasia ◽  
Life Threatening ◽  
Electrolyte Abnormalities

Severe hyperkalaemia in patients with congenital adrenal hyperplasia in association with aggravating factors such as acidosis and hypocalcaemia can cause life-threatening ventricular arrhythmias. Treatment of the underlying cause may be the only modality required in such cases. We report a 20-day-old male presenting with ventricular tachycardia due to electrolyte abnormalities in salt-losing congenital adrenal hyperplasia. Sudden cardiac deaths reported earlier in such cases thus gain credence.

Ischemia- and reperfusion-induced ventricular arrhythmias in dogs: effects of estrogen

1995 ◽  
Vol 268 (6) ◽  
pp. H2569-H2573 ◽  
Author(s):  
N. A. McHugh ◽  
S. M. Cook ◽  
J. L. Schairer ◽  
M. M. Bidgoli ◽  
G. F. Merrill
Keyword(s):  
Ventricular Tachycardia ◽  
Ventricular Arrhythmias ◽  
Coronary Perfusion Pressure ◽  
Ventricular Premature Beat ◽  
Coronary Perfusion ◽  
Ischemia And Reperfusion ◽  
Myocardial Ischemia And Reperfusion ◽  
Exogenous Estrogen ◽  
Life Threatening ◽  
Premature Beats

The purpose of this investigation was to determine if exogenous estrogen could attenuate the ventricular arrhythmias caused by myocardial ischemia and reperfusion. Conjugated equine estrogen, administered as an intravenous bolus injection (100 micrograms) to anesthetized, instrumented beagles of both genders, significantly attenuated the incidence of ventricular arrhythmias during a 20-min period of ischemia (2 +/- 1 vs. 19 +/- 16% ectopy) and in the first 5 min of reperfusion (15 +/- 9 vs. 69 +/- 20% ectopy). By 15-20 min of ischemia, ventricular salvos and nonsustained ventricular tachycardia were frequently observed in nontreated dogs. One dog in this group fibrillated during ischemia. In contrast, estrogen-treated dogs exhibited only an occasional ventricular premature beat during the same period of ischemia. When compared with baseline values, the percent ectopy during ischemia in estrogen-treated dogs was insignificant. During reperfusion, nontreated dogs displayed severe, life-threatening arrhythmias such as sustained ventricular tachycardia. In two of these dogs ventricular tachycardia deteriorated to ventricular fibrillation. In comparison, estrogen-treated dogs displayed only innocuous ventricular arrhythmias during reperfusion, i.e., ventricular premature beats, ventricular salvos, and ventricular bigeminy. In addition to the effect of estrogen on arrhythmias, there was a gradual increase in coronary blood flow on reperfusion in estrogen-treated dogs. This effect of estrogen was preceded by a significantly higher coronary perfusion pressure during ischemia (31 +/- 2 vs. 18 +/- 4 mmHg, P < 0.05). In conclusion, our findings suggest that antiarrhythmic effects of estrogen treatment might stabilize ventricular rhythmicity during ischemia and reperfusion.

Ethmozine: Electrophysiology, hemodynamics, and antiarrhythmic efficacy in patients with life-threatening ventricular arrhythmias

1986 ◽  
Vol 112 (2) ◽  
pp. 327-333 ◽  
Author(s):  
Paul Dorian ◽  
Debra S. Echt ◽  
R.Hardwin Mead ◽  
John T. Lee ◽  
Cynthia S. Lebsack ◽  
...  
Keyword(s):  
Ventricular Arrhythmias ◽  
Life Threatening ◽  
Antiarrhythmic Efficacy

scholarly journals Continuous Heart Rate Monitoring for Automatic Detection of Life-Threatening Arrhythmias With Novel Bio-Sensing Technology

2021 ◽  
Vol 8 ◽  
Author(s):  
Ehud Chorin ◽  
Aviram Hochstadt ◽  
Arie Lorin Schwartz ◽  
Gil Matz ◽  
Sami Viskin ◽  
...  
Keyword(s):  
Ventricular Tachycardia ◽  
Gold Standard ◽  
Ventricular Arrhythmias ◽  
Cardiac Rhythm ◽  
Automatic Detection ◽  
Wearable Devices ◽  
Proof Of Concept ◽  
Heart Rate Monitoring ◽  
Sensing Technology ◽  
Life Threatening

Aims: Assessing the effectiveness of novel bio-sensing technology (CardiacSense), for accuracy and reliability of automatic detection of life-threatening arrhythmias.Methods and Results: This prospective study consisted of Eighteen patients (13 males and 5 females, mean age 59.4 ± 21.3 years) undergoing induction of ventricular tachycardia/fibrillation or provocation of transient ventricular asystole. We tested the detection of provoked ventricular arrhythmias by a wrist-worn watch-like device which uses photoplethysmography (PPG) technology to detect the cardiac rhythm. We used simultaneous electrocardiographic (ECG) recordings as gold standard for arrhythmia definition and confirmation of beat-to-beat detection. A total of 1,527 QRS complexes were recorded simultaneously by ECG and PPG. The overall correlation between the ECG (R-R intervals) and the PPG (G-G intervals) was high, with a correlation coefficient of R = 0.949 (p &lt; 0.001). The device accurately detected all events of mimicked life endangering arrhythmias, including five events of transient (adenosine-induced) ventricular asystole as well as seven episodes of monomorphic ventricular tachycardia and 6 events of ventricular fibrillation.Conclusion: This proof-of-concept study suggests that wearable devices using PPG technology, currently used to detect atrial fibrillation, may also have a role as automatic detectors of life-threatening arrhythmias.

scholarly journals ОСОБЛИВОСТІ ДІАГНОСТИЧНОГО ТА МЕДИКАМЕНТОЗНО-ІНВАЗИВНОГО МЕНЕДЖМЕНТУ ЧАСТО РЕЦИДИВУЮЧОЇ ПОЛІМОРФНОЇ, ПОЛІТОПНОЇ ШЛУНОЧКОВОЇ ТАХІКАРДІЇ

2021 ◽  
Vol 25 (1-2) ◽  
pp. 72-78
Author(s):  
Т.В. Дубровінська ◽  
Ю.А. Остапчук ◽  
К.Е. Вакуленко ◽  
Б.Б. Кравчук ◽  
Н.О. Люлька ◽  
...  
Keyword(s):  
Myocardial Infarction ◽  
Ventricular Tachycardia ◽  
Ventricular Arrhythmias ◽  
Electrophysiological Study ◽  
Antiarrhythmic Therapy ◽  
Polymorphic Ventricular Tachycardia ◽  
Long Term Follow Up ◽  
Life Threatening ◽  
Complicated Course

In today's conditions, given the difficult economic situation in the country and the low adherence of patients to treatment, a difficult and relevant issue is the treatment of post-myocardial infarction patients, especially in the complicated course of the disease. The main reason for the occurrence of complex cardiac arrhythmias is the formation of a focus of ectopic activity in the myocardium or the appearance of a re-entry wave. In case of recurrence of life-threatening tachycardias, despite antiarrhythmic therapy, the choice must be between escalating drug therapy and radiofrequency catheter ablation (RFA). Purpose: a detailed description of the clinical case of the disease in a patient with low compliance to medical treatment, who suffered an acute myocardial infarction and was subsequently hospitalized several times in a specialized cardiac hospital for the development of complex ventricular arrhythmias. The article describes in detail modern approaches to the diagnosis and treatment of life-threatening tachycardias, including emergency care, comparison of escalation of antiarrhythmic therapy with RFA in a patient with post-infarction cardiosclerosis and frequent attacks of recurrent polymorphic ventricular tachycardia, treatment of modern defibrillator, electrophysiological study, RFA. Conclusions: Long-term follow-up of a patient with low compliance to the treatment of complex ventricular arrhythmias showed that ablation of the ventricular tachycardia substrate was more effective than escalation of antiarrhythmic therapy, which led to the remodulation of the heart cavities, improving the quality of life of the patient and preventing the progression of cardiovascular events.

scholarly journals Ventricular fibrillation ablation in cardiomyopathies and arrhythmic storm

2021 ◽  
Vol 23 (Supplement_E) ◽  
pp. E112-E117
Author(s):  
Carlo Pappone ◽  
Gabriele Negro ◽  
Giuseppe Ciconte
Keyword(s):  
Ventricular Tachycardia ◽  
Cardiac Death ◽  
Ventricular Arrhythmias ◽  
Healthy Individuals ◽  
Therapeutic Tool ◽  
Cardioverter Defibrillator ◽  
Structural Abnormalities ◽  
Life Threatening ◽  
Underlying Mechanisms ◽  
Screening And Prevention

Abstract Sudden cardiac death (SCD) is a relevant contributor to cardiovascular mortality, often occurring as a dramatic event. It can be the consequence of a ventricular tachycardia/fibrillation (VT/VF), a common and life-threatening arrhythmia. The underlying mechanisms of this catastrophic arrhythmia are poorly known. In fact, it can occur in the presence of a structural heart condition which itself generates the suitable substrate for this arrhythmia. Nevertheless, a VF may cause SCD also in young and otherwise healthy individuals, without overt structural abnormalities, generating difficulties in the screening and prevention of these patients. The implantable cardioverter-defibrillator represents the only therapy to contrast SCD by treating a VT/VF; however, it cannot prevent the occurrence of such arrhythmias. Catheter ablation is emerging as an essential therapeutic tool in the management of patients experiencing ventricular arrhythmias.

scholarly journals Catheter Ablation of Life-Threatening Ventricular Arrhythmias in Athletes

Medicina ◽  
2021 ◽  
Vol 57 (3) ◽  
pp. 205
Author(s):  
Nicola Tarantino ◽  
Domenico G. Della Rocca ◽  
Nicole S. De Leon De La Cruz ◽  
Eric D. Manheimer ◽  
Michele Magnocavallo ◽  
...  
Keyword(s):  
Catheter Ablation ◽  
Ventricular Arrhythmias ◽  
Individual Factors ◽  
Substantial Part ◽  
Arrhythmogenic Substrate ◽  
Life Threatening ◽  
History Of ◽  
Anatomic Distribution ◽  
Artery Disease ◽  
Surveillance Analysis

A recent surveillance analysis indicates that cardiac arrest/death occurs in ≈1:50,000 professional or semi-professional athletes, and the most common cause is attributable to life-threatening ventricular arrhythmias (VAs). It is critically important to diagnose any inherited/acquired cardiac disease, including coronary artery disease, since it frequently represents the arrhythmogenic substrate in a substantial part of the athletes presenting with major VAs. New insights indicate that athletes develop a specific electro-anatomical remodeling, with peculiar anatomic distribution and VAs patterns. However, because of the scarcity of clinical data concerning the natural history of VAs in sports performers, there are no dedicated recommendations for VA ablation. The treatment remains at the mercy of several individual factors, including the type of VA, the athlete’s age, and the operator’s expertise. With the present review, we aimed to illustrate the prevalence, electrocardiographic (ECG) features, and imaging correlations of the most common VAs in athletes, focusing on etiology, outcomes, and sports eligibility after catheter ablation.

Sign in / Sign up

Export Citation Format

Share Document